CFH rs1061142: Understanding Your Genetic Risk for AMD
The rs1061142 variant is a common genetic polymorphism located within the CFH gene. It is widely recognized in scientific literature for its statistical association with an increased risk of developing age-related macular degeneration (AMD).
What each genotype means
Lower risk profile
This genotype is considered the lower-risk version of this variant, often referred to as the Y402 allele. Research indicates that individuals with this genotype have a lower statistical association with age-related macular degeneration compared to those carrying the C allele.
This is the most common genotype in many populations, though frequencies vary significantly by ancestry.
Increased risk profile
This genotype, which includes one copy of the C allele (the H402 variant), is associated with a higher statistical risk of developing age-related macular degeneration. Studies suggest a multiplicative model where each C allele increases the odds of disease, so you should discuss regular eye health screenings with your clinician.
This heterozygous genotype is common in European populations, where the C allele frequency is approximately 0.35.
Highest risk profile
This genotype, consisting of two copies of the C allele (the H402 variant), is strongly associated with an increased risk for age-related macular degeneration. Research suggests that individuals with this genotype may have a significantly higher likelihood of developing the condition compared to those with the TT genotype, so it is important to maintain routine eye examinations and discuss your risk profile with an eye care professional.
This homozygous genotype is less common than the CT or TT genotypes in most populations, though it remains a well-documented risk factor in clinical research.
What is rs1061142?
The rs1061142 variant is a single-nucleotide polymorphism (SNP) situated within the CFH gene on chromosome 1. In genetics, a SNP represents a variation at a single position in the DNA sequence among individuals. This specific variant is frequently discussed in the context of ocular health because it resides in a region of the genome that has been repeatedly linked to the development of age-related macular degeneration (AMD). While the variant itself is a specific point in the genetic code, it often serves as a marker for broader genetic patterns in the CFH region. Researchers use this SNP to study how inherited differences in our DNA might influence the body's susceptibility to complex, age-related conditions. It is important to note that possessing this variant does not mean an individual will develop a disease; rather, it indicates a statistical shift in risk observed in large-scale population studies.
The Role of the CFH Gene
The CFH gene provides the blueprint for producing a protein known as complement factor H. This protein plays a critical role in the body's immune system, specifically within the complement system, which is a group of proteins that work together to help clear pathogens and damaged cells. By regulating this system, complement factor H prevents the immune response from becoming overactive and damaging healthy tissues. In the eye, the proper function of this protein is essential for maintaining the health of the retina. When the complement system is not properly regulated, it can lead to chronic inflammation and the accumulation of deposits known as drusen beneath the retina. These deposits are a hallmark of age-related macular degeneration. Variations in the CFH gene, such as those linked to rs1061142, may alter the structure or function of the complement factor H protein, potentially impacting how effectively the eye manages these inflammatory processes over time.
Research and Evidence Strength
The association between CFH variants and AMD is one of the most well-characterized findings in modern ophthalmic genetics. Numerous studies have demonstrated that individuals carrying specific alleles at the CFH locus face a higher statistical risk of developing AMD compared to those who do not. For instance, research has indicated that individuals homozygous for certain risk alleles may have a significantly higher likelihood of developing the condition, with some studies reporting multi-fold increases in risk. However, the evidence strength is considered limited in terms of clinical predictability for any single individual. Most people who carry these risk variants never develop the disorder, highlighting that AMD is a complex condition influenced by a combination of genetics, environmental factors, and lifestyle choices. Because the risk is probabilistic rather than deterministic, this information is primarily used for research and population-level risk assessment rather than individual diagnostic screening.
Population Frequency
The frequency of the rs1061142 variant varies significantly across different ancestral groups, which is a common observation in human genetics. Data from large-scale population databases indicate that the C allele frequency is approximately 0.35 in European populations, while it is notably lower, around 0.08, in East Asian populations. These differences underscore the importance of considering ancestry when interpreting genetic data. Because the prevalence of the variant differs by region and heritage, the baseline risk associated with the variant may also be interpreted differently depending on the population being studied. Understanding these frequency distributions helps researchers refine their models of disease risk and ensures that genetic studies are representative of diverse human populations. It also serves as a reminder that genetic markers are not distributed uniformly across the globe.
What You Can and Cannot Do With This Information
Genetic information regarding rs1061142 is intended for educational purposes and should not be used to diagnose or predict the development of eye disease. If you are concerned about your vision or your family history of macular degeneration, the most effective step is to consult with an eye care professional, such as an ophthalmologist or optometrist. They can provide comprehensive eye exams and discuss personalized strategies for maintaining eye health, such as smoking cessation, healthy diet, and UV protection, which are known to influence AMD risk regardless of your genetic profile. You cannot use this SNP data to issue medical instructions or to determine a definitive health outcome. Always discuss any genetic test results with a qualified healthcare provider who can help you interpret the findings within the context of your overall health and medical history.
How common is this variant?
The C allele frequency is approximately 0.35 in European populations and 0.08 in East Asian populations, reflecting significant ancestral variation.
Frequently asked questions
Does having the rs1061142 risk allele mean I will get AMD?
No, having a risk allele does not mean you will develop AMD. Many people with the risk variant never develop the condition, as it is influenced by many other genetic and environmental factors.
Can I change my risk if I have this variant?
While you cannot change your genetics, you can manage modifiable risk factors. Lifestyle choices like not smoking, eating a healthy diet, and protecting your eyes from UV light are recommended for everyone, regardless of their genetic profile.
Should I get tested for this SNP?
Genetic testing for this SNP is not typically recommended for the general public. If you have a family history of AMD, it is best to speak with an eye doctor about regular screenings and preventative care.
Is this variant the only cause of macular degeneration?
No, AMD is a complex disease with many contributing factors. It is associated with multiple genes, as well as age, smoking, and other environmental influences.
Sources & further reading
Educational information only, last refreshed 9/27/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1061142?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CFH
This regulatory variant in the CFH locus is linked to complement system dysregulation and is a recognized genetic risk factor for age-related macular degeneration.
This variant in the complement factor H gene is associated with altered regulation of the alternative complement pathway and increased susceptibility to age-related macular degeneration.
Intronic single nucleotide variant in the CFH region associated with susceptibility to age-related macular degeneration (AMD).
Common variant in the CFH locus strongly associated with risk of age-related macular degeneration (AMD).
Intronic marker in CFH forming critical susceptibility haplotypes for choroidal neovascularization and macular atrophy.
Intergenic/intronic variant within the CFH cluster contributing to phenotypic variation in retinal complement activation.